Arbutus Biopharma/$ABUS

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Arbutus Biopharma

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Ticker

$ABUS
Sector
Primary listing

Employees

44

ABUS Metrics

BasicAdvanced
$840M
-
-$0.29
1.01
-

Bulls say / Bears say

Arbutus regained Greater China rights for its lead RNAi therapy imdusiran in June 2025, restoring full global commercial control and access to possible milestone and royalty streams (Globe Newswire)
In Q2 2025, Arbutus reported $10.7 million total revenue and GAAP net income of $2.5 million—up from a $19.8 million loss a year ago—while holding $98.1 million in cash and equivalents, showing stronger financial performance and liquidity (Globe Newswire)
After reducing its workforce by 57% in Q1 2025 and making other cost cuts, the company ended 2024 with $123 million in cash, cash equivalents, and marketable securities—enough to fund development into late 2026 (Globe Newswire)
Q2 2025 revenue jump was due to a one-time recognition of previously deferred revenue after the Qilu Pharmaceutical partnership ended, not from underlying business growth (Ainvest)
As of the Q4 2024 update, Arbutus was still assessing its HBV pipeline and development plans, with no set start date for the Phase 2b imdusiran trial, leading to uncertain clinical timelines (Globe Newswire)
The company's value hinges largely on ongoing patent litigation against Moderna (jury trial in September 2025) and Pfizer/BioNTech (claim construction outcome pending), posing legal risks and potential expense (Globe Newswire)
Data summarised monthly by Lightyear AI. Last updated on 5 Sept 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ABUS

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs